CStone Pharmaceuticals

CStone Pharmaceuticals (HKEX: 2616) is a biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology and precision therapies to address the significant unmet medical needs of cancer patients in China and globally. Established at the end of 2015, CStone Pharmaceuticals has assembled a world-class management team with extensive experience in new drug discovery, clinical research, and commercial operations. With a core focus on combination therapies in immuno-oncology, the company has built a robust pipeline comprising 15 oncology drug candidates. To date, CStone Pharmaceuticals has received approval for five new drug applications in Greater China, including three in mainland China, one in Hong Kong, and one in Taiwan. Several late-stage drug candidates are currently in pivotal clinical trials or registration phases. The vision of CStone Pharmaceuticals is to become a globally recognized biopharmaceutical company leading the way in the fight against cancer.